Supportive Care in Cancer

, Volume 21, Issue 8, pp 2315–2320 | Cite as

Predictors of acute adverse events from rapid rituximab infusion

  • Dora S. P. Lang
  • Dorothy M. K. Keefe
  • Tim Schultz
  • Alan Pearson
Original Article

Abstract

Purpose

This study aimed to identify the predictors of acute adverse events resulting from rapid rituximab infusion over 90 min.

Method

It was a retrospective cohort study using medical record review based on a convenience sampling from 2007 till May 2011 in both in-patient and ambulatory setting in Royal Adelaide Hospital.

Results

There were a total of 294 patients who received 376 courses and 1,571 cycles of rapid rituximab infusion. Forty-three (14.6 %) patients experienced acute adverse events of hypotension being the most commonly occurring events followed by patients feeling hot and face-flushed. There were 11 predictors analysed, namely age, gender, diagnosis, stage of disease, presence of cardiac or lung morbidities, type of treatment, number of course and cycles, total white blood cells count, lymphocyte counts and lactate dehydrogenase using log generalised estimating equation for univariate and multivariate analysis. The findings successfully demonstrated that high lymphocyte counts were the independent predictor of acute adverse event from rapid rituximab infusion (p = 0.0009). Patient with high lymphocyte counts were 6.9382 times the odd to experience an adverse event as compared to those with normal lymphocyte counts.

Conclusion

There are no specific patient characteristics to preclude prescribing rapid rituximab infusion following a 90-min regimen for non-Hodgkin lymphoma except a potential for adverse events to occur when patients have abnormally high lymphocyte counts.

Keywords

Predictors Associations Rapid rituximab infusion Adverse events 

References

  1. 1.
    Aurran-Schleinitz T, Gravis G, Vittot M, Coso D, Rey J, Schiano J, et al (2005) “One Hour” rituximab infusion is safe and improves patient care and outpatient unit management. Am Soc Hematology p 4759-Google Scholar
  2. 2.
    Middleton HJ, Mollee P, Bird R, Mills AK, Marlton P, Gill D (2005) Accelerated delivery of rituximab is safe on an out-patient basis. Blood 106:Abstract 4777Google Scholar
  3. 3.
    Chiang J, Chan A, Shih V, Hee SW, Tao M, Lim ST (2010) A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol 91:826–830PubMedCrossRefGoogle Scholar
  4. 4.
    Roche (2005) Mathera. Roche Products Pty Limited [updated 8 April 2010; cited 2010 29 July 2010]; Available from: http://www.roche-australia.com/portal/eipf/australia/au/corporate/pharmaceuticals#oncology
  5. 5.
    Lang SP, George C (2011) Acute Adverse reactions of rapid rituximab infusion among adult patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. JBI Libr Syst Rev 9(1):1–37Google Scholar
  6. 6.
    Miles J, Shevlin M (2001) Applying regression and correlation. SAGE, LondonGoogle Scholar
  7. 7.
    National Cancer Institute (2010) Common terminology criteria for adverse events (CTCAE) Version 4. U.S. Department of Health and Human Services [updated 14 Jun 2010; cited 2010 31 Jul 2010]; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
  8. 8.
    SAS Institute Inc (1976) SAS 9.2 and SAS enterprise guide. SAS Institute Inc, CaryGoogle Scholar
  9. 9.
    Foa R, Di Rocco A, van Hazel G, Chamone DF, Ruffert K, Rowe JM, et al (2010) Maintenance rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: updated results from the phase IIIb MAXIMA Study. ASH Annual Meeting Abstracts. November 19, 2010, 116(21):3945-Google Scholar
  10. 10.
    DAmore F, Brincker H, Gronbaek K, Thorling K, Pedersen M, Jensen M et al (1994) Non-Hodgkin’s lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 12(8):1673Google Scholar
  11. 11.
    Armitage J, Potter J (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Sc 32(4):269Google Scholar
  12. 12.
    Vose JM, Armitage J, Weisenburger D, Bierman P, Sorensen S, Hutchins M et al (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 6(12):1838PubMedGoogle Scholar
  13. 13.
    Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN (2009) Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 84(2):93–97PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Dora S. P. Lang
    • 1
    • 2
  • Dorothy M. K. Keefe
    • 3
  • Tim Schultz
    • 4
  • Alan Pearson
    • 1
  1. 1.Faculty of Health Sciences, Joanna Briggs InstituteUniversity of AdelaideAdelaideAustralia
  2. 2.National University Cancer InstituteSingaporeSingapore
  3. 3.Royal Adelaide HospitalAdelaideAustralia
  4. 4.Australian Patient Safety FoundationAdelaideAustralia

Personalised recommendations